Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind, Parallel-group, Phase III Study to Compare the Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera® in Subjects With Previously Untreated (CD)20-Positive LTB Follicular Lymphoma

NCT03976102 is registered in ClinicalTrials.gov with Dr. Reddy's Laboratories Limited as lead sponsor.

NCT NCT03976102
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03976102 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind, Parallel-group, Phase III Study to Compare the Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera® in Subjects With Previously Untreated (CD)20-Positive LTB Follicular Lymphoma
Lead sponsor
Dr. Reddy's Laboratories Limited
Phase
Phase 3
Overall status
Completed
Start date
May 15, 2019
Completion date
February 27, 2023
Enrollment
317 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

follicular lymphoma